Early decrease in serum IV-7S levels during IFN treatment predicts anti-fibrogenic effect in nonresponders with...

Area of Science:

• Hepatology
• Fibrosis research
• Viral hepatitis treatment

Background:

• Chronic hepatitis C (CHC) poses a significant risk of liver fibrosis.
• Interferon (IFN) therapy is used to treat CHC, but predicting long-term outcomes remains challenging.
• Fibrogenic markers may offer insights into treatment response.

Purpose of the Study:

• To determine if early changes in serum fibrogenic markers during IFN treatment can predict long-term anti-fibrogenic effects in CHC patients.
• To evaluate the predictive value of N-terminal peptide of type III procollagen (P-III-NP) and 7S domain of type IV collagen (IV-7S) levels.
• To assess these markers in IFN-nonresponders and compare them with untreated controls.

Main Methods:

• Retrospective analysis of serum P-III-NP and IV-7S levels in 56 CHC IFN-nonresponders and 43 untreated controls.
• Measurements taken before, during, and at multiple time points after IFN cessation.
• Comparison of marker levels between treatment groups and over time.

Main Results:

• In nonresponders, both P-III-NP and IV-7S levels decreased significantly long-term after IFN therapy.
• P-III-NP levels showed an early decrease at 1 month (T1) and remained low.
• Early decrease in IV-7S at T1 predicted favorable long-term anti-fibrogenic effects, especially in patients with later IV-7S reduction.
• Untreated patients showed increased fibrogenic markers over time.

Conclusions:

• An early decrease in IV-7S levels following IFN treatment is a valuable predictor of anti-fibrogenic effects in CHC nonresponders.
• This marker can help assess the long-term impact of IFN therapy on liver fibrosis.
• Monitoring IV-7S levels early in treatment may guide therapeutic strategies for CHC.